Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects

Diabetes Care

Volumn 26, Issue 2, 2003, Pages 285-289

  Tsunekawa, Taku ^b   Hayashi, Toshio ^a   Suzuki, Yusuke ^b   Matsui Hirai, Hisako ^b   Kano, Hatsuyo ^b   Fukatsu, Akiko ^b   Nomura, Noriko ^b   Miyazaki, Asaka ^b   Iguchi, Akihisa ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ADIPONECTIN; C PEPTIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIDIABETIC AGENT; DRUG DERIVATIVE; PROSTAGLANDIN F2 ALPHA; PROTEIN; SIGNAL PEPTIDE; SULFONYLUREA DERIVATIVE;

AGED; AGING; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC CLEARANCE RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PROTEIN URINE LEVEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; OSMOLARITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; AGED; DIABETES MELLITUS, TYPE 2; DINOPROST; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINS; SULFONYLUREA COMPOUNDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042593396     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.2.285     Document Type: Article

References (30)

1. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
2. Grundy SM: Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 105:2696-2698, 2002
3. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
4. Couet C, Delarue J, Constans T, Lamisse F: Aged-related insulin resistance: a review. Horm Res 38:46-50, 1992
5. Carvalho CR, Brenelli SL, Silva AC, Nunes AL, Velloso LA, Saad MJ: Effect of aging on insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of rats. Endocrinology 137:151-159, 1996
6. Rizza RA, Mandarino LJ, Gerich JE: Mechanism and significance of insulin resistance in non-insulin-dependent diabetes mellitus. Diabetes 30:990-995, 1981
7. Kaburagi Y, Yamauchi T, Yamamoto-Honada R, Ueki K, Tobe K, Akanuma Y, Yazaki Y, Kadowaki T: The mechanism of insulin-induced signal transduction mediated by the insulin receptor substrate family. Endocr J 46:S25-S34, 1999
8. Rosak C: The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J Diabetes Complications 16:123-132, 2002
9. Clark HE, Mattews DR: The effect of glimepiride on pancreatic β-cell function under hyperglycaemic clamp and hyper-insulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 28:445-450, 1996
10. Muller G: The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol Med 6:907-933, 2000
11. Volk A, Maerker E, Rett K, Haring HU, Overkamp D: Glimepiride: effects on peripheral insulin sensitivity. Diabetologia 43 (Suppl. 1):A39, 2000
12. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133, 2001
13. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
14. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acutephase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137, 2002
15. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Shoji T, Okuno Y, Morii H: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22:818-822, 1999
16. Bonora E, Forementini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G, Bonadonna R, Muggeo M: HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25:1135-1141, 2002
17. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Futura M, Araki-Sasaki R, Hori Y, Yano Y, Adachi Y: Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 24:362-365, 2001
18. Defronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:214-223, 1979
19. Greenfield MS, Doberne L, Kraemer FT: Insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 30:387-392, 1981
20. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasama concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vase Biol 20:1595-1599, 2000
21. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
22. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM: Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376-380, 2002
23. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
24. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723-1732, 2000
25. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF: Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 51:1319-1336, 2002
26. Muller G, Wied S: The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 42:1852-1867, 1993
27. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA: The expression of TNFα by human muscle. J Clin Invest 97:1111-1116, 1996
28. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Kumar N, Egashira K, Iguchi A: Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104:376-379, 2001
29. Sampson MJ, Gopaul N, Davies IR, Hughes DA, Carrier MJ: Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care 25:537-541, 2002
30. Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E, Robkamp R: Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 28:419-425, 1996